



Inflammatory Bowel Disease

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report **Inflammatory Bowel Disease Q2 2011**

Therapeutic Class:	Autoimmune Disorders, Gastroenterology
Focus Area:	Crohn's disease, ulcerative colitis
Specialty/Location:	Gastroenterologists/N. America, Europe
Number of Interviews:	6
Number of Pages:	140
Publication Date:	June 2011
Principal Authors:	Tricia L. Hanlon Kim Grant Jeffrey D. Berk, Ph.D., MBA
Product Code:	MGIQ211-12
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract: Gastroenterology Thought Leader Panel #12 summarizes our discussions with six internationally recognized experts in the treatment of Crohn's disease and ulcerative colitis. These took place following DDW, May 2011.

The Panel was most interested in opining on recent clinical data related to four groups of therapeutics: TNF, integrin/adhesion/MAdCAM, IL-23 and JAK. They predict the likelihood of approvals and use in the treatment of inflammatory bowel disease. Key mechanisms discussed in this report include TNF, integrin/MAdCAM, p40 (IL-23, IL-12, p19), IL-6 / JAK1 / JAK3, IL-17, CCR9 and stem cell transplant.

Full transcripts of six qualitative interviews with gastroenterologists are included with this report.

Drugs mentioned in this report include:

Company	Generic	Brand
Abbott (Eisai)	adalimumab briakinumab; ABT-874	Humira (with Eisai)
Ablynx / Pfizer	ATN-103	
Allostera	APG-2305	
Amgen	AMG-827	
Astra-Zeneca / Rigel	fostamatinib	
Avaxia	AVX-470; polyclonal bovine anti-TNF	
Celgene	PDA001	
ChemoCentryx / GlaxoSmithKline	CCX-282 B	Traficet-EN
Elan / Biogen	natalizumab	Tysabri
Emergent / Pfizer	X1 TNFR x Anti-IL6	
Ferring	FE-301	
Genentech / Roche	rhuMAb-b7; RG7413	
J&J / Janssen / Merck / Essex	infliximab ustekinumab; CNTO-1275 golimumab	Remicade Stelara Simponi
Lilly	INCB-28050 / LY3009104	
Merck (Schering-Plough)	SCH-900222	
Millennium / Takeda	vedolizumab (MLN-02)	
Novartis	secukinumab; AIN-457	
Osiris Therapeutics	mesenchymal stem cell	Prochymal
Pfizer	tofacitinib; CP-690550 PF-00547659	
Pfizer/Athersys	PF-0528541	MultiStem
UCB	certolizumab	Cimzia
Vertex	VX-509	

Table of Contents

EXECUTIVE SUMMARY 4

Report Highlights 5

KEY FINDINGS 10

General Comments 10

Steroid Sparing..... 10

Mucosal Healing..... 15

Patients’ Parenteral Preference..... 16

TNF 17

Remicade (infliximab; Janssen) 17

Humira (adalimumab; Abbott)..... 27

Cimzia (certolizumab; UCB) 34

Simponi; golimumab (Janssen / Schering-Plough / Merck) 37

AVX-470 Avaxia 39

ATN-103 (Anti-TNF α ; Ablynx / Pfizer) 39

X1 TNFR x Anti-IL-6/IL-6R SCORPION™ Therapeutic (Pfizer / Emergent) 39

Integrin / MAdCAM 40

Tysabri (natalizumab; Biogen / Elan) 40

vedolizumab (MLN-02 / MLN-0002; Takeda)..... 44

RG7413; rhuMAb-b7 (Genentech) 52

PF-00547659 (Pfizer)..... 53

p40: Anti-IL-12 / Anti-IL-23 54

Stelara (ustekinumab / CNTO-1275; Janssen) 54

SCH900222 (p19 IL-23 selective MAb; Merck / Schering-Plough) 58

JAK / Syk / IL6 59

tofacitinib / tasocitinib; CP-690550 (Pfizer)..... 59

INCB 28050 (LY 3009104; Lilly / Incyte) 66

ALX-0061 (anti-IL6R; Ablynx) 66

CDP6038 (UCB) 67

FE301 (Ferring / Conaris) 68

fostamatinib (Rigel / AZ) 68

VX-509 (Vertex)..... 69

IL-17 70

secukinumab; AIN-457 (Novartis)..... 70

AMG-827 (Amgen) 71

Immunosuppressants / Immunomodulators 73

Imuran (azathioprine) 73

CCR9 76

Traficet-EN (CCX-282-B; ChemoCentryx/GSK) 76

Steroids	78
Santaris	78
Stem Cell Transplant	79
Prochymal (Osiris Therapeutics)	81
PDA-001; Celgene Cellular Therapeutics	84
MultiStem; PF-0528541 (Athersys / Pfizer)	85

THOUGHT-LEADER DISCUSSIONS 86

Interview OHIID02566	86
Interview OHIID02567	96
Interview OHIID02568	107
Interview OHIID02569	115
Interview OHIID02570	123
Interview OHIID02571	131